Shares in this article
The Tübingen group CureVac has presented its figures for the third quarter and the first nine months of the current financial year.
Accordingly, the company, which is listed on the NASDAQ, generated revenues of 5.16 million euros in the past quarter, after 1.096 million euros in the same quarter of the previous year. From January to September, CureVac had a total turnover of 42.83 million euros. In the same period a year before, sales were 10.6 million euros.
The bottom line was that the company continued to write deep red figures: In the third quarter, the net loss was 36.83 million euros (previous year’s quarter: 18.36 million euros), and over the entire nine-month period there was a net loss of 70.78 million euros. For comparison: In the first three quarters of 2019, the net loss was 63.88 million euros.
CureVac owed the jump in sales primarily to a payment from its pharmaceutical partner GlaxoSmithKline. With the development of its Covid-19 vaccine, CureVac sees itself on course and plans to start the approval-relevant study shortly.
CureVac announced that it would begin the study with around 36,000 participants by the end of the year. The company also wants to get a partner on board for this purpose. Curevac recently published positive interim results from the phase 1 study with the vaccine.
CureVac shares temporarily gain 6.96 percent to 91.98 US dollars on the NASDAQ.
Finanzen.net / Reuters editors
More news about GlaxoSmithKline plc (GSK)
Image sources: Matthias Hangst / Getty Images